111 related articles for article (PubMed ID: 38052106)
1. Epidermal growth factor potentiates EGFR(Y992/1173)-mediated therapeutic response of triple negative breast cancer cells to cold atmospheric plasma-activated medium.
Wang P; Zhou R; Zhou R; Feng S; Zhao L; Li W; Lin J; Rajapakse A; Lee CH; Furnari FB; Burgess AW; Gunter JH; Liu G; Ostrikov KK; Richard DJ; Simpson F; Dai X; Thompson EW
Redox Biol; 2024 Feb; 69():102976. PubMed ID: 38052106
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade.
Martin JL; de Silva HC; Lin MZ; Scott CD; Baxter RC
Mol Cancer Ther; 2014 Feb; 13(2):316-28. PubMed ID: 24337110
[TBL] [Abstract][Full Text] [Related]
3. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.
Brand TM; Iida M; Dunn EF; Luthar N; Kostopoulos KT; Corrigan KL; Wleklinski MJ; Yang D; Wisinski KB; Salgia R; Wheeler DL
Mol Cancer Ther; 2014 May; 13(5):1356-68. PubMed ID: 24634415
[TBL] [Abstract][Full Text] [Related]
4. Specific epidermal growth factor receptor autophosphorylation sites promote mouse colon epithelial cell chemotaxis and restitution.
Yamaoka T; Frey MR; Dise RS; Bernard JK; Polk DB
Am J Physiol Gastrointest Liver Physiol; 2011 Aug; 301(2):G368-76. PubMed ID: 21617115
[TBL] [Abstract][Full Text] [Related]
5. Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer.
Madden JM; Mueller KL; Bollig-Fischer A; Stemmer P; Mattingly RR; Boerner JL
Breast Cancer Res Treat; 2014 Sep; 147(2):283-93. PubMed ID: 25129346
[TBL] [Abstract][Full Text] [Related]
6. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
8. IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells.
Merrouche Y; Fabre J; Cure H; Garbar C; Fuselier C; Bastid J; Antonicelli F; Al-Daccak R; Bensussan A; Giustiniani J
Oncotarget; 2016 Aug; 7(33):53350-53361. PubMed ID: 27462789
[TBL] [Abstract][Full Text] [Related]
9. Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of Cannabidiol in breast cancer.
Elbaz M; Nasser MW; Ravi J; Wani NA; Ahirwar DK; Zhao H; Oghumu S; Satoskar AR; Shilo K; Carson WE; Ganju RK
Mol Oncol; 2015 Apr; 9(4):906-19. PubMed ID: 25660577
[TBL] [Abstract][Full Text] [Related]
10. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells.
Meyer AS; Miller MA; Gertler FB; Lauffenburger DA
Sci Signal; 2013 Aug; 6(287):ra66. PubMed ID: 23921085
[TBL] [Abstract][Full Text] [Related]
11. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
McLaughlin RP; He J; van der Noord VE; Redel J; Foekens JA; Martens JWM; Smid M; Zhang Y; van de Water B
Breast Cancer Res; 2019 Jul; 21(1):77. PubMed ID: 31262335
[TBL] [Abstract][Full Text] [Related]
12. Growth hormone-releasing hormone induced transactivation of epidermal growth factor receptor in human triple-negative breast cancer cells.
Vacas E; Muñoz-Moreno L; Valenzuela PL; Prieto JC; Schally AV; Carmena MJ; Bajo AM
Peptides; 2016 Dec; 86():153-161. PubMed ID: 27816751
[TBL] [Abstract][Full Text] [Related]
13. Diverse injurious stimuli reduce protein tyrosine phosphatase-μ expression and enhance epidermal growth factor receptor signaling in human airway epithelia.
Hyun SW; Anglin IE; Liu A; Yang S; Sorkin JD; Lillehoj E; Tonks NK; Passaniti A; Goldblum SE
Exp Lung Res; 2011 Aug; 37(6):327-43. PubMed ID: 21649524
[TBL] [Abstract][Full Text] [Related]
14. Partial agonistic effect of cetuximab on epidermal growth factor receptor and Src kinase activation in triple‑negative breast cancer cell lines.
Gurdal H; Tuglu MM; Bostanabad SY; Dalkiliç B
Int J Oncol; 2019 Apr; 54(4):1345-1356. PubMed ID: 30720056
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.
Corkery B; Crown J; Clynes M; O'Donovan N
Ann Oncol; 2009 May; 20(5):862-7. PubMed ID: 19150933
[TBL] [Abstract][Full Text] [Related]
16. Regulation of low-density lipoprotein receptor expression in triple negative breast cancer by EGFR-MAPK signaling.
Scully T; Kase N; Gallagher EJ; LeRoith D
Sci Rep; 2021 Sep; 11(1):17927. PubMed ID: 34504181
[TBL] [Abstract][Full Text] [Related]
17. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
18. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression.
Peng XH; Karna P; Cao Z; Jiang BH; Zhou M; Yang L
J Biol Chem; 2006 Sep; 281(36):25903-14. PubMed ID: 16847054
[TBL] [Abstract][Full Text] [Related]
19. ELP-dependent expression of
Cruz-Gordillo P; Honeywell ME; Harper NW; Leete T; Lee MJ
Sci Signal; 2020 Nov; 13(658):. PubMed ID: 33203722
[TBL] [Abstract][Full Text] [Related]
20. Fatty acid binding protein 5 promotes metastatic potential of triple negative breast cancer cells through enhancing epidermal growth factor receptor stability.
Powell CA; Nasser MW; Zhao H; Wochna JC; Zhang X; Shapiro C; Shilo K; Ganju RK
Oncotarget; 2015 Mar; 6(8):6373-85. PubMed ID: 25779666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
